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Abstract 
1,1,2-Trisnorsqualenoic acid was conjugated to paclitaxel to obtain the squalenoyl–paclitaxel 
prodrug with the aim to improve the incorporation in phospholipid bilayers. Differential scanning 
calorimetry technique was employed to compare the interaction of squalenoyl–paclitaxel prodrug 
and free paclitaxel with phospholipid bilayers. The possibility of using lipid vesicles as carrier for 
the prodrug was also evaluated. An increased encapsulation into phospholipid bilayers of 
squalenoyl–paclitaxel with respect to the free drug was observed. The ability of lipid vesicles to 





 Paclitaxel (Taxol®) is an antineoplastic agent that is derived from the bark of the Pacific yew tree 
(Taxus brevifolia) (Wani et al., 1971). Paclitaxel has been used to treat ovarian carcinoma, breast 
carcinoma, leukemia, melanoma, prostate carcinoma etc. (Choi and Jo, 2004). Its transport and 
delivery is obstacolated by a very low water solubility (Vyas, 1995) then, at the present, it is 
formulated in a mixture of 50:50% (v/v) polyoxyethylated castor oil (Cremophor EL) and 
dehydrated ethanol. However, this formulation vehicle has been found to cause serious side-effects, 
  
including hypersensitivity and neurotoxicity reactions (Weiss et al., 1990; Fjallskog et al., 1993). 
Then, there is a continued interest in finding formulations that can be administered easily and 
safely. Water-soluble paclitaxel derivatives have been prepared and their activity has been 
investigated (Greenwald et al., 1996, 2003; Ceruti et al., 2000; Singer et al., 2003). Alternatively, 
paclitaxel has been encapsulated in biodegradable polymers (Mu and Feng, 2003; Liu et al., 2010; 
Nanda et al., 2011). Moreover, cyclodextrins (Alcaro et al., 2002) emulsion (Han et al., 2004; 
Constantinides et al., 2004) microspheres (De et al., 2005; Jackson et al., 2007) nanoparticles 
(Bhardwaj et al., 2009; Chakravarthi et al., 2010) formulation have been prepared and investigated. 
The incorporation of paclitaxel in vesicular carrier has been attempted (Meng et al., 2010; Paolino 
et al., 2012). However, the amount of paclitaxel that can be incorporated into lipid bilayers is 
limited (Sharma et al., 1998; Shieh et al., 1997; Balasubramanian and Straubinger, 1994). 
Therefore, it could be of interest to use a lipid-based prodrug of paclitaxel that could be 
incorporated and retained in lipid carrier preparations. Some attempt has been done to achieve this 
goal. 2 -Alpha-bromohexadecanoyl paclitaxel prodrug has been synthetized and incorporated in 
lipid systems that were found more effective than paclitaxel against a human ovarian tumor (Ahmad 
et al., 1999). We have exploited the conjugation of a lipophilic moiety to some drug in order to 
increase their affinity for lipid systems with respect to the free drug. In those researches we have 
utilized as lipophilic moiety 1,1 ,2-trisnorsqualenoic acid (squaleneCOOH) (Castelli et al., 2007; 
Sarpietro et al., 2009, 2010, 2011) a derivative of squalene, a compound widespread in nature, that 
is synthesized within cells and consumed as an integral part of the human diet. The prodrugs 
obtained showed a deep interaction with phospholipid bilayers. Following this approach, in the 
present research, we conjugated squaleneCOOH with paclitaxel with the aim to obtain a highly 
lipophilic squalenoyl–paclitaxel prodrug (Scheme 1)  that can be incorporated and retained into the 
lipid system. The interaction of the prodrug with lipid bilayers represented by 
dimyristoylphosphatidylcholine (DMPC) multilamellar vesicles (MLV) has been investigated by 
differential scanning calorimetry technique that can reveal the effect caused by the insertion of 
“stranger” molecules in the phospholipid bilayers through the variation of the phospholipid bilayers 
thermotropic parameters (transition temperature, Tm, enthalpy change, H) induced by the 
incorporated molecules. Transmembrane experiments have been also carried out to verify the ability 
of the prodrug to be retained in the lipid system. 
 
2. Materials and methods 
 2.1. Materials Synthetic 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, purity 99%) was 
obtained from Genzyme (Switzerland). Paclitaxel was purchased from Indena (Milan, Italy), other 
  
reagents were purchased from Sigma–Aldrich (Milwaukee, WI). The NMR spectra were recorded 
using a NMR Bruker Avance 300 spectrometer. Elemental analyses were carried out by Redox Snc 
(Monza, Italy). All HPLC analyses were performed on a Merck-Hitachi L- 6200 Liquid 
Chromatographer equipped with L5000 LC Controller (Merck, Milan, Italy) and the eluting 
fractions containing PTX were monitored at 227 nm using an L-4200 UV detector. 
 
 2.2. Synthesis and characterization of squalenoyl–paclitaxel 
 Paclitaxel (1.2 g, 1.4 mmol), dissolved in 30 ml of dichloromethane, was reacted with N-ethyl-N -
3-dimethylaminopropyl carbodiimide (0.6 equiv.), in the presence of 4- dimethylamino pyridine 
(0.2 equiv.) and 1,1 ,2-trisnorsqualenoic acid (0.6 equiv.) previously dissolved in DCM at room 
temperature. After 3 h, the reaction was stopped with water and extracted with brine. The crude 
mixture was purified by chromatography on SiO2 eluted with a gradient (from 95:5 to 80:20) of 
dichloromethane/ethyl acetate to give the pure compound (1) (Scheme 1) (Yield 65%). TLC control 
dichloromethane/ethanol (97:3) Rf 0.55. The purity of squalenoyl–paclitaxel was checked by HPLC 
on a RP-18 reverse phase column (LiChrospher 100 RP 18e 5 m, Merck) eluted with an 
acetonitrile/water mixture (40:60 and, after 5 min, gradient up to 100% acetonitrile, 20 min), elution 
time 19.23 min. Purity by HPLC was above 92%. Characterization: 1H NMR (300 MHz, CDCl3): 
8.13 (d, 2H, C23, C27ArH), 7.75 (d, 2H, C39, C43 ArH), 7.62 (t, 1H, C25 ArH), 7.53–7.49 (band, 
3H, C24, C26, C41 ArH), 7.43–7.35 (band, 7H, C33, C34, C35, C36, C37, C40, C42 ArH), 6.91 
(d,1H, 4 NH), 6.35 (s, 1H, C(10)-H), 6.24 (m, 1H, C(13)-H), 5.99 (dd, 1H, C(3 )-H), 5.69 (d, 1H, 
C(2)-H), 5.53 (d, 1H, C(2 )-H), 5.20 (m, 5H, C(SQ-H)), 4.97 (d, 1H, C(5)-H), 4.44 (m, 1H, C(7)-
H), 4.33 (d, 1H, C(20)-Ha), 4.20 (d, 1H, C(20)-Hb), 3.85 (d, 1H, C(3)-H), 2.55 (m, 1H, C(6)-Ha), 
2.49 (s, 3H, C(29)-H), 2.45 (m, 2H, CH2–CH2–CO SQ), 2.30 (t, 2H, CH2–CH2–CO SQ), 2.23 (s, 
3H, C(31)-H), 2.09 (s, 3H, C(18)-H), 2.00 (m, 16H, CH2 SQ), 1.97 (m, 1H, C(6)-Hb), 1.70 (m, 1H, 
C(14)-Ha), 1.67 (s, 3H, C(19)-H), 1.61 (m, 18H, C(SQ)–CH3), 1,25 (m, 1H, C(14)-Hb), 1.21 (s, 
3H, C(16)-H), 1.13 (s, 3H, C(17)-H). ESI-MS calculated for C74H93NO15: 1235.65. Found 
1237.24 (MH+). Elemental analysis calc: C 71.88%, H 7.58%, N 1.13%; measured C 71.99%, H 
7.63%, N 1.19%.  
The lipophilic character of the synthesized compound was determined using a chromatographic Rm 
method as described by some of us (Dosio et al., 2010). Theoretical log P was calculated using the 
software ALOGPS 2.1 available on the Web site http://www.vcclab.org/lab/alogps/start.html.  
 
2.3. Differential scanning calorimetry. 
  
 Differential scanning calorimetry studies were performed using a Mettler TASTARe System 
equipped with a DSC822e cell and a Mettler STARe V8.10 software. The reference pan was filled 
with 120 µl of 50 mM TRIS. The calorimetric system was calibrated, in transition temperature and 
enthalpy changes, by using indium and palmitic acid (purity ≥ 99.95% and ≥99.5%, respectively; 
Fluka, Switzerland) following the procedure of the Mettler STAR software.  
 
2.4. Multilamellar vesicles preparation. 
 Multilamellar vesicles were prepared empty and loaded with compounds. Stock solutions of 
DMPC, paclitaxel and squalenoyl–paclitaxel were prepared in chloroform/methanol (1:1, v/v). 
Aliquots of DMPC solution corresponding to 0.010325 mmol were put in glass tubes and aliquots 
of paclitaxel or squalenoyl–paclitaxel were added to have the following molar fraction of 
compounds with respect to DMPC: 0.00, 0.015, 0.03, 0.045, 0.06, 0.09, 0.12. The solvents were 
evaporated under a nitrogen stream and the obtained films were freeze dried to eliminate solvents 
traces. 168 µl of 50 mM TRIS (pH 7.4) was added to the films and the samples were heated at 37 
◦C (temperature higher than the DMPC Tm) for 1 min and vortexed for 1 min, for three times and, 
then, left in a water bath at 37 ◦C for 60 min. 
 
 2.5. MLV/paclitaxel and MLV/squalenoyl–paclitaxel interaction. 
 120 µl of the MLV (0.007375 mmol of DMPC) were put in a 160 µl aluminium pan which was 
hermetically closed and submitted to calorimetric scans, for at least three times, as follows: (i) a 
heating scan from 5 to 37 ◦C, at 2 ◦C/min; (ii) a cooling scan from 37 to 5 ◦C, at 4 ◦C/min. The 
experiments were carried out in triplicate to be sure of the results reproducibility.  
 
2.6. Paclitaxel and squalenoyl–paclitaxel absorption by MLV. 
 120 µl of MLV were put in the calorimetric pan where an amount of drug or prodrug 
corresponding to a 0.09 molar fraction with respect the DMPC had been weighted. The pan was 
closed and submitted to calorimetric scans as follows: (i) a heating scan from 5 to 37 ◦C, at 2 
◦C/min; (ii) a isothermal scan of 60 min at 37 ◦C; (iii) a cooling scan from 37 to 5 ◦C, at 4 ◦C/min; 
for at least eight times.  
 
2.7. Evaluation of liposomes as carrier of squalenoyl–paclitaxel. 
 In this kind of experiments MLV were considered both as lipophilic carrier for paclitaxel and 
squalenoyl–paclitaxel and as biomembrane model. In particular compound loaded MLV were used 
as carrier whereas unloaded MLV were used as biomembrane model. The point of this experiment 
  
was that loaded MLV mixed with unloaded MLV at a temperature higher than the Tm can transfer 
the loaded compound to unloaded MLV so after several incubation periods an equilibrium between 
MLV could be reached. 60 l of unloaded MLV (prepared without compound) were put in the 
calorimetric pan and 60 l of loaded MLV (prepared with paclitaxel or squalenoyl–paclitaxel at 0.06 
molar fractions with respect to the DMPC) were added. The pan was closed and submitted to the 
same calorimetric scans described in the previous section. 
 
 3. Results and discussion  
We have conjugated paclitaxel with squaleneCOOH to obtain the squalenoyl–paclitaxel prodrug 
(Scheme 1). This derivative was obtained by linkage atthe 2 -hydroxyl group of paclitaxel, as 
several previously synthesized taxoids (Skwarczynski et al., 2006). Derivatives obtained exploiting 
this position are much more accessible to enzymes and are able to undergo hydrolysis so as to 
release the active drug. In the reported experimental conditions the ester in 2 position was the most 
relevant derivative obtained while the 7-hydroxyl reacted only after an almost complete titration of 
2 hydroxyl using a larger amount of squaleneCOOH and N-ethyl-N - 3-dimethylaminopropyl 
carbodiimide reagent (1–1.4 equiv.). The achieved products were clearly identified following the 
NMR spectra at 4.44 ppm (7 –CH–OH proton) and 4.78 ppm (2 –CH–OH proton). Its relative 
lipophilicity factor (Rm) together with that of paclitaxel was evaluated. The experimental 
evaluation was compared with theoretical log P values. It was observed that squalene moiety 
strongly increased the lipophilicity of paclitaxel. Experimental and theoretical evaluations were in 
agreement (Table 1). The interaction of the prodrug with biomembrane model was evaluated and 
compared with that of paclitaxel. With this aim, MLV were prepared empty and loaded with the 
drug or the prodrug and submitted to DSC analysis. The interaction of the compounds with MLV 
was evaluated comparing the calorimetric curves of the MLV with compound with that of MLV 
without compound (Fig. 1A and B). In fact, any compound interacting with MLV phospholipids 
produces a variation of the calorimetric curve of MLV; usually the variation is dependent on the 
amount of compound interacting with MLV. The calorimetric heating thermogram of MLV made of 
DMPC alone exhibits two thermal events, a lower-temperature, less energetic endotherm centered 
at about 17 ◦C, corresponding to the well characterized pretransition, and a higher-temperature, 
more energetic endotherm centered at about 24.8 ◦C, which correspond to the main or chain-melting 
phase transition of DMPC (Lewis et al., 1987). The incorporation of paclitaxel in the MLV 2 mW 
produces some variation in the MLV thermogram (Fig. 1A). The pretransition is abolished; the 
main phase transition peak is gradually shifted toward lower temperature and broadened for molar 
fraction of paclitaxel up to 0.06 but turns to higher temperature and sharp for molar fraction of 
  
paclitaxel >0.06. Moreover, when the molar fraction of paclitaxel is >0.015 and 0.03, a two-
component main phase transition is evident which indicates a not homogeneous distribution of the 
prodrug in the bilayers and, hence the presence in the bilayer of regions of phospholipids that are 
rich in prodrug and perturbed and of regions of phospholipids poor in prodrug and less perturbed 
(Lohner and Prenner, 1999; Lambros and Rahman, 2004). The stronger interaction of squalenoyl–
paclitaxel with biomembrane with respect to paclitaxel could be due to its increased lipophilicity 
that in turn increases the affinity for the phospholipid bilayers. As described above, we put 
paclitaxel or squalenoyl–paclitaxel (molar fraction = 0.09) in contact with MLV and submitted the 
samples to subsequent calorimetric scans separated by isothermal (37 ◦C) periods of 60 min. This 
experiment was carried out to evaluate the capability of the drug and prodrug to migrate through the 
aqueous medium and subsequently be absorbed by MLV. If this occurred the calorimetric behavior 
of MLV should change due to the presence of the compounds within the bilayers. The calorimetric 
thermograms shown in Fig. 2 are compared with the calorimetric thermogram of MLV prepared 
without compound and with that of MLV prepared with compound at 0.09 molar fraction. The latter 
thermogram is used as reference as it should be obtained if the compound was absorbed by MLV. 
There is not evidence of variation in MLV behavior neither when paclitaxel nor when squalenoyl–
paclitaxel are used which indicate the inability of the two compounds to dissolve in the aqueous 
medium and be absorbed by MLV, as expected given the hydrophobic nature and the water 
insolubility of the compounds. Liposomes have been widely investigated for their properties as 
potential drug delivery systems (Gregoriadis, 1988). They have become a valuable experimental 
and commercially important drug delivery system, due to their biodegradability, biocompatibility 
and ability to entrap lipophilic and hydrophilic drugs (Torchilin, 2005). In this research MLV were 
used as biomembrane model as well as drug carrier; in particular, we evaluated the capability of 
MLV to retain the incorporated prodrug and, then, their possible use as prodrug carrier. With this 
aim we put prodrug loaded MLV (prodrug carrier) in contact with unloaded MLV (biomembrane 
model) and submitted the sample to calorimetric scans at intervals of 60 min during which the 
temperature was kept at 37 ◦C. For comparison reasons the experiment with paclitaxel was carried 
out too. The loaded MLV were prepared with 0.06 molar fraction of compound. This molar fraction 
was chosen as it exerted the highest effect on MLV, with concern to paclitaxel (see Fig. 1A). The 
calorimetric thermograms are compared with those of unloaded and loaded MLV which were put in 
contact and with that of MLV prepared with 0.03 molar fraction of drug or prodrug (reference 
curve) (Fig. 3A and B). If the carrier was able to hold the compound incorporated, the calorimetric 
thermograms should remain unchanged; if, instead, the carrier lost the compound, we should 
observe some variation in the calorimetric thermograms which should look like the reference 
  
thermogram. What we see in Fig. 3A, relative to paclitaxel, is only the disappearance of the 
pretransition peak while the main transition peak remains unchanged. With regard to squalenoyl–
paclitaxel (Fig. 3B), the calorimetric thermograms show three components: the first (at about 17 ◦C) 
is attributable to the pretransition; the second (a large shoulder from about 21 to 24 ◦C) attributable 
to loaded MLV and the third (at about 24.8 ◦C) relative to unloaded MLV. They remain almost 
unchanged for all the incubation times meaning that the lipophilic carrier holds the incorporated 
prodrug. This means that the MLV may be used as a carrier while maintaining the drug loaded up to 
inside the cell. 
 
4. Conclusion  
Starting from the evidence that only a small amount of paclitaxel can be incorporated into 
liposomes, we conjugated the drug to 1,1,2-trisnorsqualenoic acid with the aim to obtain a molecule 
with a stronger affinity with the phospholipid bilayers and that can, consequently, be incorporated 
and retained in the lipid system. The results obtained clearly indicate an improved incorporation 
efficiency of squalenoyl–paclitaxel with respect to paclitaxel into the liposome, probably due to its 
stronger lipophilic character. In addition, liposome can retain the incorporated squalenoyl–
paclitaxel and hence a lipid system could be considered as a possible carrier for the prodrug. 
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